| 80.99 1.94 (2.45%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 95.99  |
1-year : | 99.66 |
| Resists | First : | 82.18 |
Second : | 85.33 |
| Pivot price | 79.76 |
|||
| Supports | First : | 77.09 | Second : | 64.14 |
| MAs | MA(5) : | 78.91 |
MA(20) : | 80.37 |
| MA(100) : | 82.89 |
MA(250) : | 79.8 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 38.1 |
D(3) : | 24.5 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 87.88 | Low : | 68.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EW ] has closed below upper band by 26.3%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 81.79 - 82.09 | 82.09 - 82.34 |
| Low: | 77.98 - 78.36 | 78.36 - 78.66 |
| Close: | 80.41 - 81.01 | 81.01 - 81.48 |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Mon, 20 Apr 2026
Mirae Asset Global Investments Co. Ltd. Increases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Sun, 19 Apr 2026
Lecap Asset Management Ltd. Invests $1.07 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Sat, 18 Apr 2026
Edwards Lifesciences Corporation $EW Shares Bought by Ninety One SA Pty Ltd - MarketBeat
Sat, 18 Apr 2026
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One UK Ltd - MarketBeat
Fri, 17 Apr 2026
Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Moves? - simplywall.st
Fri, 17 Apr 2026
Lbp Am Sa Buys 107,330 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 577 (M) |
| Shares Float | 579 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 92.2 (%) |
| Shares Short | 10,950 (K) |
| Shares Short P.Month | 7,900 (K) |
| EPS | 1.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.79 |
| Profit Margin | 17.6 % |
| Operating Margin | 23.7 % |
| Return on Assets (ttm) | 7.6 % |
| Return on Equity (ttm) | 10.3 % |
| Qtrly Rev. Growth | 13.3 % |
| Gross Profit (p.s.) | 8.2 |
| Sales Per Share | 10.52 |
| EBITDA (p.s.) | 3.1 |
| Qtrly Earnings Growth | -76.6 % |
| Operating Cash Flow | 1,600 (M) |
| Levered Free Cash Flow | 1,170 (M) |
| PE Ratio | 44.74 |
| PEG Ratio | 0 |
| Price to Book value | 4.55 |
| Price to Sales | 7.69 |
| Price to Cash Flow | 29.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|